
|Articles|October 1, 2012
Unapproved neurotoxins abound, dermatologist warns
The approval of the newest botulinum toxin product available in the United States underscores the value of the Food and Drug Administration drug approval process and the importance of using branded products, says Mich?l H. Gold, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
3
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
4
Top 5 Articles of the Week: December 7-12
5


















